Frontiers in Clinical Drug Research - Alzheimer Disorders is an e-Book series which covers recent topics related to understanding Alzheimer's disease (AD) that causes dementia and has a neurodegenerative effect on the brain. The disease affects memory, thought process, and language of affected individuals. Chapters in each volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in field of Alzheimer’s Disease research. The fifth volume of this series features chapters covering critical discussions on AD management and new therapies. The topics reviewed in this volume include: - Current concepts in management of AD - The amyloid cascade hypothesis and stem cell-based AD therapy - Phytochemicals targeting AD - Dementia screening in primary clinical care settings - Updates in dementia / AD clinical research and drug development

Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in field of Alzheimer’s disease research.

Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD), a disease that causes dementia, or loss of brain function. This disease affects parts of the brain that affect memory, thought, and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders.

Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD), a disease that causes dementia, or loss of brain function. This disease affects parts of the brain that affect memory, thought and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders. </p> <p> Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in the field of Alzheimer’s disease research. </p> <p> The eighth volume of this series features chapters covering critical discussions on new therapies for AD. The reviews in this volume include: </p> <p> - Novel Molecular Targets of Tauopathy; Therapeutic and Diagnostic Applications </p> <p> - The Therapy of Alzheimer’s Disease: Towards a New Generation of Drugs </p> <p> - Could Antibiotics Be Therapeutic Agents in Alzheimer’s Disease? </p> <p> - Use of Antipsychotics in Patients with Alzheimer’s Disease </p> <p> - Approaches Based on Cholinergic Hypothesis and Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease </p> <p> - Potential Biological Mechanisms with Prophylactic Action in Rapid Cognitive Impairment in Late-Onset Alzheimer's Disease </p>

This eBook compiles the efforts of 20 experts in the field to review the latest advances in experimental stroke, with its strong emphasis on neurogenesis, angiogenesis and neuroprotection after cerebral ischemic stroke. It also provides current data for pharmacologic therapy, including anti-Inflammation, for stroke. Several chapters address cell death and apoptotsis after stroke as well as its replacement strategies by stem cells. Other chapters deal with the relation between stroke and neuroimmunology, BBB disruption and electrophysiological changes. Also covered is magnetic resonance imaging in ischemic brain. In a variety of preclinical models of stroke, pre-conditional and post-conditional stroke models will be discussed.

Frontiers in Clinical Drug Research – Central Nervous System presents the latest research and clinical studies on the central nervous system (CNS). It covers a range of topics such as the development and pathophysiology of the brain and spinal cord, physiological sites of drug action in the CNS and clinical findings on drugs used to treat CNS defects due to injury or impaired development. In addition to clinical research on humans, the book also highlights other avenues of CNS medicine and research such as pain medicine, stem cell research, pharmacology, toxicology and translational models in animals. The first volume of the series features chapters on the following topics: -Nerve targets in pain medicine -Spinal cord injury -Research on neurotoxins targeting voltage gated ion channels -G protein coupled receptor agonists and modulators -Drug research on mediating hypoxia in developing white matter

Frontiers in Clinical Drug Research – Central Nervous System presents the latest researches and clinical studies on the central nervous system (CNS). It covers a range of topics such as the development and pathophysiology of the brain and spinal cord, physiological sites of drug action in the CNS and clinical findings on drugs used to treat CNS defects due to injury or impaired development. In addition to clinical research on humans, the book also highlights other avenues of CNS medicine and research such as pain medicine, stem cell research, pharmacology, toxicology and translational models in animals. The second volume of the series features chapters on the following topics: - Nucleic acids as drugs for neurodegenerative diseases - Cellular Cysteine Network (CYSTEINET): - Non-motor Symptoms in Parkinson’s Disease and drug therapies - Multi-modal pharmacological treatments for major depressive disorder

<p></p> Frontiers in Clinical Drug Research - Dementia is a book series which presents comprehensive reviews about research on Dementia, - the loss of brain function associated with Alzheimer’s disease and other related medical conditions. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for dementia and related disorders. <p></p> This volume includes the following reviews: <p></p> - Meeting the Challenges of Falls and Hip Fractures in People with Alzheimer’s Disease <p></p> - Cholesterol in Brain Health and Pathologies <p></p> - Advances in the Treatment of Mild Cognitive Impairment (MCI) and Dementia <p></p> - Analytical Methods in Alzheimer’s Disease Drug Discovery <p></p> - Targeting Alzheimer’s Disease through Nanomedicine <p></p> - Current Challenges in Alzheimer’s Disease Research <p></p> - Metals Linked to Alzheimer's Disease <p></p>

Among neurodegenerative diseases, those that lead to a state of dementia are the aim of several investigations. Dementia is a chronic disease the prevalence of which is increasing worldwide. The number of dementia patients in the world is approximately 50 million, and it is estimated that the number of patients will reach 131.5 million by 2050. This increase will be accompanied by a significant increase in medical expenditures and other expenses, especially for elderly patients. Therefore, the maintenance cost of dementia in the future is expected to be quite high. For this reason, several investigations aim, firstly, to describe the key mechanisms involved in the origin of dementia and, secondly, to establish preventive and therapeutic strategies in order to understand and mitigate this debilitating pathology. &lt;p&gt; This volume of Frontiers in Clinical Drug Research - Dementia explores the current comorbidities that cause cognitive impairment and the current management alternatives for clinical cases of dementia. The reviews contributed in these volume will provide readers with a current perspective on the subject. The topics covered in this volume include: &lt;p&gt; - Comorbidities inducing mild cognitive impairment - an evaluation of the risk caused by some pathological conditions &lt;p&gt; - Tau-targeted therapy in Alzheimer's disease - history and current state &lt;p&gt; - Emerging nanotherapeutic strategies in Alzheimer's disease &lt;p&gt; - Implication of dehydroepiandrosterone on dementia related to oxidative stress &lt;p&gt; - Polyphenol compounds as potential therapeutic agents in Alzheimer&rsquo;s disease &lt;p&gt; The volume is a timely update on dementia treatment for clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.

This e-book is a reference on Selegiline/(-)-Deprenyl effects on the brain. Selegiline, described in thousands of research papers, is registered in over 60 countries. At present, more than one hundred preparations containing selegiline circulate in the global market under different brand names. They are widely used in the treatment of Parkinson&rsquo;s disease, Alzheimer&rsquo;s disease, major depression and as a geroptotective / anti-aging drug. (-)-Deprenyl/selegiline, the first selective inhibitor of B-type MAO which, in contrast to the known MAO inhibitors, did not potentiate the effect of tyramine but inhibited it. The compound could be combined with levodopa in Parkinson&rsquo;s disease without signs of hypertensive reactions. The DATATOP study in the USA revealed that (-)-deprenyl delayed the onset of disability associated with early, otherwise untreated Parkinson&rsquo;s disease. The age-related decay of the supply of the brain with phenylethylamine ( PEA), due to the progressive increase of MAO-B activity in the aging brain, and dopamine, due to the better than average decline of the dopaminergic neuronal activity during the postdevelopmental phase of life, are irresistible biochemical lesions of aging. The speed of deterioration of behavioral performances with the passing of time and longevity depends significantly on the pace of the worsening of these leasions. (-)-Deprenyl, Increasing the supply of the brain with PEA and dopamine, counteracts this aging process. Maintenance of male rats from sexual maturity until death on (-)-deprenyl delays the age-related loss of the capacity to ejaculate, slows the age-related decline of learning ability and prolongs life. In humans, maintenance from sexual maturity on (-)-deprenyl (1 mg daily) is, for the time being, the most promising prophylactic treatment to fight against the age-related decay of behavioral performances, prolonging life, and preventing or delaying the onset of age-related neurodegenerative diseases such as Parkinson&rsquo;s and Alzheimer&rsquo;s. This e-book is a useful reference for graduate medical students, academic researchers in the field of neuropsychopharmacology, neurophysiology and gerontology and professional research groups in commercial organizations manufacturing selegiline preparations.